• By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.
OK
Advertisement
Yesterday
In the last 7 days
Cardiovascular Risks of Chimeric Antigen Receptor T-Cell Therapy Journal of American Medical Associations16:53 7-Oct-24
NUHS’s CD7 CAR-T cell therapy shows promise for leukaemia Pharmaceutical Technology10:08 7-Oct-24
In the last month
Type 2 immune response may boost CAR-T British Society for Haematology09:37 30-Sept-24
Hemogenyx Pharmaceuticals readies for phase I trial Proactive Investors (US)07:42 27-Sept-24
Programming cells to target brain tumors ScienceDaily00:38 27-Sept-24
Programming cells help to fight a brain tumor Tech Explorist13:13 26-Sept-24
Improving CAR-T Cell Efficacy via New Manufacturing Process Genetic Engineering and Biotechnology News17:37 18-Sept-24
FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1 Pharmaceutical Technology10:40 17-Sept-24
Risk of second cancers after CAR-T assessed British Society for Haematology09:10 16-Sept-24
Using a molecular scissors to improve CAR-T cell therapy Newswise (Press Release)16:15 12-Sept-24
view more headlines
11 Oct 20:17

About our CAR-T news

Latest news on CAR-T (Chimeric Antigen Receptor T-cell) therapy, a type of cancer treatment that involves modifying patients' T-cells to recognize and attack cancer cells. In this therapy, T-cells are collected from the patient, engineered in a lab to express a specific receptor that binds to a protein on cancer cells, and then infused back into the patient to fight the cancer. CAR-T therapies have shown promise in treating certain types of blood cancers, like lymphoma and leukemia.


Publication filters

Headline Density

Sorry, no headlines or news topics were found. Please try different keywords.